Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › everolimus

everolimus

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of everolimus

151 trials tracked of everolimus: 46 in phase 3 or 4 and 14 with published results. The most-cited published study has 1268 citations.

151Trials tracked
46Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 19 Phase 3 27 Phase 2 91 Phase 1 11 Other / NA 3
  1. Phase 3 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) Completed · 1,268 cited
  2. Phase 3 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Completed · 492 cited
  3. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 307 cited
  4. Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) Completed · 241 cited
  5. Phase 3 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed · 66 cited
  6. Phase 3 Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients Completed · 58 cited
Show 44 more trials
  1. Phase 3 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Completed · 49 cited
  2. Phase 3 Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen Completed · 35 cited
  3. Phase 4 Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant Completed · 31 cited
  4. Phase 4 Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients Completed · 30 cited
  5. Phase 4 Novartis Everolimus Transition Completed · 13 cited
  6. Phase 3 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients Completed · 13 cited
  7. Phase 4 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Completed · 10 cited
  8. Phase 4 Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients Completed · 8 cited
  9. Phase 4 SCHEDULE Follow Up Visit 5-7 yr Completed
  10. Phase 4 Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant Completed
  11. Phase 4 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Completed
  12. Phase 4 Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. Completed
  13. Phase 4 Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus Completed
  14. Phase 4 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Completed
  15. Phase 4 Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation Completed
  16. Phase 4 Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Completed
  17. Phase 4 Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients Completed
  18. Phase 4 Everolimus in de Novo Heart Transplant Recipients Completed
  19. Phase 4 SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance Completed
  20. Phase 4 Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients Completed
  21. Phase 4 24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients Completed
  22. Phase 4 Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients Completed
  23. Phase 3 A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients Completed
  24. Phase 3 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium Completed
  25. Phase 3 Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients Completed
  26. Phase 3 Everolimus in de Novo Kidney Transplant Recipients Completed
  27. Phase 3 REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy Completed
  28. Phase 3 Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed
  29. Phase 3 RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency Completed
  30. Phase 3 Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids Completed
  31. Phase 3 Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. Completed
  32. Phase 3 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed
  33. Phase 3 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy Completed
  34. Phase 3 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed
  35. Phase 3 Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Completed
  36. Phase 3 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed
  37. Phase 3 Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients Completed
  38. Phase 3 Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection Completed
  39. Phase 3 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed
  40. Phase 3 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. Completed
  41. Phase 2 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Completed
  42. Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
  43. Phase 2 Treg Modulation With CD28 and IL-6 Receptor Antagonists Completed
  44. Phase 2 LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy Completed

Showing the 50 most-cited and recently-updated of 151 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Metabolic reprogramming and plasticity drive tumor progression and resistance through interconnected transcription factors and enzymes
Oncology Sys. Review
Metabolic reprogramming and plasticity drive tumor progression and resistance through interconnected transcription factors and enzymes Metabolic Plasticity Drives Cancer Growth and Resistance
This narrative review examines how metabolic reprogramming, driven by transcription factors like MYC and HIF-1α, facilitates cancer progress…
Cancer cells rewire their metabolism to fuel growth and resist treatment. A new review maps the complex network behind this process.
Frontiers Jul 29, 2026
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients
Cardiology RCT
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients New iron scaffold matches metal stents for heart artery repair
This randomized trial enrolled 518 patients with myocardial ischemia and 1 or 2 de novo target lesions at 36 centers in China.
A new iron heart scaffold matches metal stents in safety and effectiveness while dissolving over time.
Apr 29, 2026